Similar articles for PMID: 29324537

Year	Number of Results
1992	2
1993	1
1995	1
1999	3
2000	1
2001	1
2004	1
2005	1
2008	2
2011	3
2012	8
2013	9
2014	8
2015	13
2016	22
2017	26
2018	27
2019	22
2020	8
2021	11
2022	16
2023	9
2024	0

1

The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.

Tajik P, van de Vrie R, Zafarmand MH, Coens C, Buist MR, Vergote I, Bossuyt PMM, Kenter GG. Tajik P, et al. Int J Gynecol Cancer. 2018 Mar;28(3):453-458. doi: 10.1097/IGC.0000000000001186. Int J Gynecol Cancer. 2018. PMID: 29324537

2

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer.

Sørensen SM, Høgdall C, Mosgaard BJ, Dalgaard MIR, Jensen MP, Fuglsang K, Schnack TH. Sørensen SM, et al. Acta Obstet Gynecol Scand. 2022 Mar;101(3):334-343. doi: 10.1111/aogs.14319. Epub 2022 Feb 21. Acta Obstet Gynecol Scand. 2022. PMID: 35187660 Free PMC article.

3

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.

Gao Y, Li Y, Zhang C, Han J, Liang H, Zhang K, Guo H. Gao Y, et al. J Ovarian Res. 2019 Sep 13;12(1):85. doi: 10.1186/s13048-019-0562-9. J Ovarian Res. 2019. PMID: 31519183 Free PMC article.

4

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. Reuss A, et al. Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15. Int J Gynecol Cancer. 2019. PMID: 31420412

5

Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV. Lee J, et al. Cancer Chemother Pharmacol. 2018 Jul;82(1):55-63. doi: 10.1007/s00280-018-3591-y. Epub 2018 Apr 27. Cancer Chemother Pharmacol. 2018. PMID: 29704010

6

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators. Vergote I, et al. Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413383

7

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?

Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A. Ataseven B, et al. Gynecol Oncol. 2016 Aug;142(2):243-7. doi: 10.1016/j.ygyno.2016.05.021. Epub 2016 May 25. Gynecol Oncol. 2016. PMID: 27208538

8

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.

Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze PA, Akladios C, Costaz H, Lavoué V, Canlorbe G, Collinet P, Touboul C, Huchon C, Bricou A, Dridi S, Padéano MM, Bengrine L, Arnould L, Coutant C; Groupe de Recherche FRANCOGYN. Vincent L, et al. Eur J Surg Oncol. 2020 Sep;46(9):1689-1696. doi: 10.1016/j.ejso.2020.04.029. Epub 2020 Apr 24. Eur J Surg Oncol. 2020. PMID: 32417154

9

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. Chi DS, et al. Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13. Gynecol Oncol. 2012. PMID: 21917306

10

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.

Wang D, Zhang G, Peng C, Shi Y, Shi X. Wang D, et al. J Ovarian Res. 2021 Mar 27;14(1):49. doi: 10.1186/s13048-021-00801-4. J Ovarian Res. 2021. PMID: 33771198 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

171 results

Results by year